摘要
目的研究瑞舒伐他汀对载脂蛋白E基因缺陷小鼠(ApoE-/-小鼠)动脉粥样硬化处补体因子H(CFH)表达的影响。方法 8周龄ApoE-/-小鼠随机分为4组:模型组Ⅰ(高脂饲料喂养10周)、模型组Ⅱ(高脂饲料喂养20周)、预防组(在给予高脂饲料的同时予瑞舒伐他汀预防性给药10周)和治疗组(于高脂饲料喂养10周后,给予瑞舒伐他汀,喂至20周)。阶段试验结束时取主动脉做HE染色及免疫组化,检测CFH mRNA转录和蛋白表达水平;检测血脂及血清hsCRP、C3a水平。结果与模型组Ⅰ和模型组Ⅱ比较,预防组及治疗组ApoE-/-小鼠主动脉内膜和斑块内CFH表达增多;CFH的mRNA转录水平和蛋白表达水平升高;血脂、hsCRP、C3a水降低(P<0.01或0.05)。结论瑞舒伐他汀降低血脂水平,降低动脉粥样硬化的炎症免疫反应,增加CFH表达。
Purpose To investigate the effect of rosuvastatin on expression of complement factor H （CFH） in atherosclerosis （AS） of apolipoprotein E-knockout （ApoE-/-） Mice. Methods Eight weeks old ApoE-/-mice were divided randomly into four groups[ model group I ： AS model fed for 10 weeks（n = 14）, model group II ： AS model fed for 20 weeks （ n = 14 ）, prevention group （ n = 8 ） and treatment group（n = 8） 1. After experiment, the aortas were taken for HE, immunohistochemistry CFH stain, RT- PCR and western blotting at the 10th and 20th week with continuous intragastrie administration respective- ly. Results The CFH expression is outstanding in prevention group and treatment group than that in mod- el group I and I1. Prevention or therapy with rosuvastatin could upregulate CFH mRNA expression and increase the level of CFH protein. Serum hsCRP,and C3a levels were signifieantly decreased in the pre- vention group and treatment group relative to model group I and II （P 〈 0.01 ,or 0.05）. Conclusion Rosuvastatin can increase the expression of CFH.
出处
《中国生化药物杂志》
CAS
CSCD
北大核心
2011年第6期458-462,共5页
Chinese Journal of Biochemical Pharmaceutics
基金
南京医科大学科技发展基金资助(2010NJMUZ52)
